Cyclopharm's first patients imaged with Technegas

Cyclopharm Limited’s (ASX: CYC) has announced that first patients have been imaged in a multicentre PRONOSPECT clinical trial across 13 nuclear medicine centres in France.

PRONOSPECT is a clinician driven trial integrating Technegas into advanced imaging modalities to set new benchmarks in the diagnosis and management of recurring pulmonary embolism (PE).

The trial is examining the potential of nuclear medicine imaging using Technegas to enable improved detection of residual pulmonary vascular obstruction (RPVO) as a predictor of venous thromboembolism (VTE) – which is a clinical area currently dominated by incumbent CT pulmonary angiogram (CTPA) scanning.

Key Highlights:

• Successful Imaging Initiated: First 15 of a total of 665 patients have been imaged.
• Innovative Technegas Technology: Technegas utilised as the primary ventilation agent used for ventilation/perfusion (V/Q) SPECT/CT imaging to assess RPVO.
• Study Objectives: To establish RPVO as a predictor of VTE recurrence, improving patient phenotyping and treatment protocols to include clinical guidelines.
• Potential Global Impact: Results to redefine diagnostic protocols for managing recurring PE and enhance global adoption of Technegas-supported imaging.
• Market Growth Potential: Supporting Cyclopharm’s growth strategy, underpinned by the expanding demand for precision pulmonary diagnostics.

The study aims to establish whether RPVO, as identified via V/Q SPECT/CT imaging, is an independent predictor of VTE recurrence. It also seeks to refine diagnostic protocols and identify patients at high risk of recurrent VTE, thereby guiding individualised treatment decisions.

"The imaging of the first patients using Technegas in the PRONOSPECT trial marks another milestone in our strategy to expand the use of Technegas,” James McBrayer CEO of Cyclopharm, said.

“This study validates Technegas' capabilities in advanced pulmonary diagnostics and aligns with our commitment to improving global healthcare outcomes. We look forward to sharing the trial results, which we believe will have implications for patient care and our commercial strategy."